Introduction
The approach to patients with a narrow right ventricular outflow tract (RVOT) and reduced pulmonary blood flow, as classically seen in Tetralogy of Fallot, is mostly surgical -either by creating a systemic-to-pulmonary artery shunt or by undertaking complete repair.
Creation of a systemic-to-pulmonary artery shunt however remains high risk surgery in particular in infants with younger age and lower weight, or associated lesions, such as atrioventricular septal defect, or co-existing syndromes (mortality around 10%). Neonatal complete repair remains rare in the UK (CCAD data).
Previously transcatheter techniques, including balloon valvuloplasty and stenting, to address a very narrow right ventricular outflow tract have been described, without having gained widespread acceptance.
This report describes the single-centre experience with stenting of the RVOT in a series of 47 patients who were judged to be at high risk for initial surgical palliation or complete repair.
Methods
Retrospective case note review and data analysis of patients undergoing RVOT stenting at a single tertiary centre over a 7 year period.
Patients
Between 2005-2012, 47 selected patients underwent cardiac catheterization with a view to stent a very narrow RVOT to improve pulmonary blood flow.
Management of all individual patients was discussed in a multi-disciplinary team meeting. Surgical intervention (creation of a systemic-to-pulmonary artery shunt, outflow tract patch or complete repair) was considered in all. If surgery was deemed high risk, patients were considered for stent implantation into the right ventricular outflow tract.
In 3 patients the procedure was abandoned due to unfavorable anatomy.
Median age at stent implantation was 63 (range 5-406) days.
Median weight was 3.9 kg (1.7-12.2 kg), with 15 patients weighing less than 3 kg, including 7 weighing less than 2.5 kg. 
Results
Forty-four patients underwent stent implantation with one procedural death (2.3 %). Premounted coronary stents (Boston Liberte) were used in 31 pts. Cook Formula 414 stents were used in 8 patients. 
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